Indian frankincense

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• allergic rhinitis [Insufficient Evidence]
• Alzheimer disease [Insufficient Evidence]
• arthralgia, aromatase inhibitor-induced [Insufficient Evidence]
• asthma [Insufficient Evidence]
• back pain [Insufficient Evidence]
• brain tumor [Insufficient Evidence]
• cluster headache [Insufficient Evidence]
• COVID-19 [Insufficient Evidence]
• Crohn disease [Insufficient Evidence]
• diabetes mellitus, type 2 [Insufficient Evidence]
• diarrhea [Insufficient Evidence]
• dysmenorrhea [Insufficient Evidence]
• exercise-induced muscle soreness [Insufficient Evidence]
• IBS [Insufficient Evidence]
• knee pain [Insufficient Evidence]
• heavy menstrual bleeding [Insufficient Evidence]
• microscopic colitis [Insufficient Evidence]
• osteoarthritis [Possibly Effective]
• pain, acute [Insufficient Evidence]
• pharyngitis [Insufficient Evidence]
• postop pain [Insufficient Evidence]
• prostatitis and chronic pelvic pain syndrome [Insufficient Evidence]
• rheumatoid arthritis [Insufficient Evidence]
• rhinosinusitis [Insufficient Evidence]
• stroke [Insufficient Evidence]
• traumatic brain injury [Insufficient Evidence]
• ulcerative colitis [Insufficient Evidence]
• urinary incontinence [Insufficient Evidence]
• UTI [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

Alzheimer disease

[Insufficient Evidence]

Dose: 1200 mg PO qd

arthralgia, aromatase inhibitor-induced

[Insufficient Evidence]

Dose: 40 mg PO qd

asthma

[Insufficient Evidence]

Dose: 300 mg PO tid

back pain

[Insufficient Evidence]

Dose: 5 mg boswellic acid PO qd; Alt: 300 mg PO qd (extract ratio 3:1 boswellia:turmeric)

brain tumor

[Insufficient Evidence]

Dose: 1400 mg PO tid

COVID-19

[Insufficient Evidence]

Dose: 300 mg PO bid; Info: used with licorice and standard tx

diabetes mellitus, type 2

[Insufficient Evidence]

Dose: 500-1200 mg PO qd

diarrhea

[Insufficient Evidence]

Dose: 250 mg PO bid

dysmenorrhea

[Insufficient Evidence]

Dose: 10 mg boswellic acid PO x1; Start: on day of menstruation; Info: used with turmeric

exercise-induced muscle soreness

[Insufficient Evidence]

Dose: 10 mg boswellic acid PO x1; Alt: 60 mg PO qd starting 6 days before exercise, then continuing on day of, and 3 days after exercise; Info: used with turmeric

IBS

[Insufficient Evidence]

Dose: 250 mg PO qd

heavy menstrual bleeding

[Insufficient Evidence]

Dose: 300 mg PO tid x7 days

microscopic colitis

[Insufficient Evidence]

Dose: 400 mg PO tid

osteoarthritis

[Possibly Effective]

Dose: 15-1000 mg/day PO divided qd-tid; Alt: 7.2 mg boswellic acid PO qd; 150-300 mg boswellic acid PO bid

pain, acute

[Insufficient Evidence]

Dose: 10 mg boswellic acid PO qd; Info: used with turmeric

postop pain

[Insufficient Evidence]

Dose: 200 mg PO bid; Info: used with bromelain

rheumatoid arthritis

[Insufficient Evidence]

Dose: 200 mg PO tid

rhinosinusitis

[Insufficient Evidence]

Dose: 125-250 mg PO qd; Info: for patients 12 yo and older

stroke

[Insufficient Evidence]

Dose: 800 mg boswellic acid PO tid

traumatic brain injury

[Insufficient Evidence]

Dose: 360-400 mg PO tid; Info: used with or without ginger

ulcerative colitis

[Insufficient Evidence]

Dose: 300-350 mg PO tid; Alt: 250 mg PO qd

urinary incontinence

[Insufficient Evidence]

Dose: 300 mg PO bid

UTI

[Insufficient Evidence]

Dose: 200 mg PO qd